Stephen Jolles

School of Medicine

: jollessr@cardiff.ac.uk

2024

Shillitoe, B. et al. 2024. Outcomes of X-linked Agammaglobulinaemia patients. Journal of Clinical Immunology 45(1), article number: 40. (10.1007/s10875-024-01829-z)
Ciznár, P. et al. 2024. fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study. Allergy, Asthma & Clinical Immunology 20(1), article number: 47. (10.1186/s13223-024-00904-9)
O'Brien, O. et al. 2024. Immune response to vaccination in people with psychotic disorders relative to healthy controls: prospective study of SARS-CoV-2 vaccination. BJPsych Open 10(2), article number: e49. (10.1192/bjo.2024.10)
Griffiths, K. et al. 2024. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain, Behavior, and Immunity 115, pp. 223-228. (10.1016/j.bbi.2023.10.001)

2023

Sams, L., Wijetilleka, S., Ponsford, M., Gennery, A. and Jolles, S. 2023. Atopic manifestations of inborn errors of immunity. Current Opinion in Allergy and Clinical Immunology 23(6), pp. 478-490. (10.1097/ACI.0000000000000943)
Jefferson, L., Ramanan, A. V., Jolles, S., Bernatoniene, J., Mathieu, A., Belot, A. and Roderick, M. R. 2023. Phenotypic variability in PRKCD: a review of the literature. Journal of Clinical Immunology 43, pp. 1692-1705. (10.1007/s10875-023-01579-4)
Sewell, B. et al. 2023. The cost of implementing the COVID-19 shielding policy in Wales. BMC Public Health 23, article number: 2342. (10.1186/s12889-023-17169-3)
Giralt, S. et al. 2023. Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 23, pp. 719-732. (10.1016/j.clml.2023.05.008)
Porter, A. et al. 2023. Rationale for the shielding policy for clinically vulnerable people in the UK during the COVID-19 pandemic: a qualitative study. BMJ Open 13, article number: e073464. (10.1136/bmjopen-2023-073464)
Zaloum, S. et al. 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29(8), pp. 979-989. (10.1177/13524585231185247)
de Toledo Piza, C. F. S., Aranda, C. S., Solé, D., Jolles, S. and Condino-Neto, A. 2023. Screening for antibody deficiencies in adults by serum electrophoresis and calculated globin. Journal of Clinical Immunology (10.1007/s10875-023-01536-1)
Minskaia, E. et al. 2023. Autosomal dominant STAT6 Gain of function causes severe atopy associated with lymphoma. Journal of Clinical Immunology (10.1007/s10875-023-01530-7)
Snooks, H. et al. 2023. Did the UK's public health Shielding policy protect the clinically extremely vulnerable during the Covid-19 pandemic in Wales? Results of EVITE Immunity, a link data retrospective study. Public Health 218, pp. 12-20. (10.1016/j.puhe.2023.02.008)
Leiding, J. W. et al. 2023. Monogenic early-onset lymphoproliferation and autoimmunity: natural history of STAT3 gain-of-function syndrome. Journal of Allergy and Clinical Immunology 151(4), pp. 1081-1095. (10.1016/j.jaci.2022.09.002)
Yegit, O. O. et al. 2023. Calculated globulin is clinically useful as a screening test for antibody deficiency in Turkish adult patients. International Archives of Allergy and Immunology (10.1159/000528986)
Jolles, S., Giralt, S., Kerre, T., Lazarus, H. M., Mustafa, S. S., Ria, R. and Vinh, D. C. 2023. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. Frontiers in Oncology 13 (10.3389/fonc.2023.1098326)

2022

Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22(5), pp. 344-357. (10.1136/practneurol-2022-003370)
Grigoriadou, S. et al. 2022. British Society for Immunology & United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy. Clinical and Experimental Immunology 210(1), pp. 1-13. (10.1093/cei/uxac070)
Shields, A. M. et al. 2022. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clinical and Experimental Immunology 209(3), pp. 247-258., article number: uxac008. (10.1093/cei/uxac008)
Evans, B. A. et al. 2022. Evaluation of the shielding initiative in Wales (EVITE Immunity): protocol for a quasi-experimental study. BMJ Open 12, article number: e059813. (10.1136/bmjopen-2021-059813)
Morgan, C., Jolles, S., Ponsford, M. J., Evans, K. and Carne, E. 2022. Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding. Current Opinion in Allergy and Clinical Immunology 22(6), pp. 371-379. (10.1097/ACI.0000000000000864)
Dixon, P. H. et al. 2022. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements. Nature Communications 13(1), article number: 4840. (10.1038/s41467-022-29931-z)
Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64, article number: 103937. (10.1016/j.msard.2022.103937)
Asderakis, A. et al. 2022. An analysis of serological response and infection outcomes following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 vaccines in kidney and kidney pancreas transplants. Transplantation 106(7), pp. 1421-1429. (10.1097/tp.0000000000004105)
Saud, Z. et al. 2022. Mechanically ventilated patients shed high titre live SARS-CoV2 for extended periods from both the upper and lower respiratory tract. Clinical Infectious Diseases 75(1), pp. e82-e88., article number: ciac170. (10.1093/cid/ciac170)
Ponsford, M. J. et al. 2022. COVID-19 vaccine uptake and efficacy in a national immunodeficiency cohort. Journal of Clinical Immunology 42, pp. 728-731. (10.1007/s10875-022-01223-7)
Ponsford, M. J. et al. 2022. Examining the utility of extended laboratory panel testing in the emergency department for risk stratification of patients with COVID-19: a single-centre retrospective service evaluation. Journal of Clinical Pathology 75(4), pp. 255-262. (10.1136/jclinpath-2020-207157)
Shears, A. et al. 2022. Clinical outcome and underlying genetic cause of functional terminal complement pathway deficiencies in a multicenter UK cohort. Journal of Clinical Immunology 42, pp. 665-671. (10.1007/s10875-022-01213-9)
Hashem, H. et al. 2022. Correction to: Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. Journal of Clinical Immunology (10.1007/s10875-022-01280-y)
Pararajasingam, A., Bradley, R. E., Evans, J., Lowe, A., Goodwin, R. and Jolles, S. 2022. Case Report: Generalised panniculitis as a post-COVID-19 presentation in Aicardi-Goutières Syndrome treated with ruxolitinib. Frontiers in Pediatrics 10, article number: 837568. (10.3389/fped.2022.837568)
Warnatz, K. et al. 2022. Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies. Clinical Immunology 236, article number: 108938. (10.1016/j.clim.2022.108938)
Forbes, L. R. et al. 2022. Genetic errors of immunity distinguish pediatric non-malignant lymphoproliferative disorders. Journal of Allergy and Clinical Immunology 149(2), pp. 758-766. (10.1016/j.jaci.2021.07.015)
Brown, L. K. et al. 2022. Treatment of chronic or relapsing COVID-19 in immunodeficiency. Journal of Allergy and Clinical Immunology 149(2), pp. 557-561. (10.1016/j.jaci.2021.10.031)
Lippe, C. et al. 2022. Heterozygous variants in ZBTB7A cause a neurodevelopmental disorder associated with symptomatic overgrowth of pharyngeal lymphoid tissue, macrocephaly, and elevated fetal hemoglobin. American Journal of Medical Genetics Part A 188(1), pp. 272-282. (10.1002/ajmg.a.62492)
Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
Bradley, R. E. et al. 2022. Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report. Journal of Clinical Immunology 42, pp. 32-35. (10.1007/s10875-021-01158-5)
Dimitrova, D. et al. 2022. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. Journal of Allergy and Clinical Immunology 149(1), pp. 410-421. (10.1016/j.jaci.2021.04.036)
Jolles, S., Smith, B. D., Vinh, D. C., Mallick, R., Espinoza, G., DeKoven, M. and Divino, V. 2022. Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. Leukemia & Lymphoma 63(1), pp. 64-73. (10.1080/10428194.2021.1992761)
Moat, S. J. et al. 2022. Maternal SARS-CoV-2 sero-surveillance using newborn dried blood spot (DBS) screening specimens highlights extent of low vaccine uptake in pregnant women. Human Vaccines and Immunotherapeutics 18(5), article number: 2089498. (10.1080/21645515.2022.2089498)
Sewell, B. et al. 2022. P3 How Much Did the COVID-19 Shielding Policy Cost in Wales? Results of a Cost Analysis Within the EVITE Immunity Evaluation. Value in Health 25(12) (10.1016/j.jval.2022.09.015)

2021

Sedivá, A., Milota, T., Litzman, J., Quinti, I., Meyts, I., Burns, S. and Jolles, S. 2021. Medical algorithm: diagnosis and management of antibody immunodeficiencies. Allergy 76(12), pp. 3841-3844. (10.1111/all.14961)
Ponsford, M. J. et al. 2021. Burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults. Thorax 76(12), pp. 1246-1249. (10.1136/thoraxjnl-2021-216964)
Petrov, A. A., Adatia, A., Jolles, S., Nair, P., Azar, A. and Walter, J. E. 2021. Antibody deficiency, chronic lung disease, and comorbid conditions: a case based approach. Journal of Allergy and Clinical Immunology: In Practice 9(11), pp. 3899-3908. (10.1016/j.jaip.2021.09.031)
Shillitoe, B. M. J. et al. 2021. Haematopoietic stem cell transplant for norovirus-induced intestinal failure in X-linked agammaglobulinemia. Journal of Clinical Immunology 41, pp. 1574 -1581. (10.1007/s10875-021-01088-2)
Hashem, H. et al. 2021. Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. Journal of Clinical Immunology 41, pp. 1633-1647. (10.1007/s10875-021-01098-0)
Ponsford, M. J. et al. 2021. A systematic review and meta-analysis of inpatient mortality associated with nosocomial and community COVID-19 exposes the vulnerability of immunosuppressed adults. Frontiers in Immunology 12, article number: 744696. (10.3389/fimmu.2021.744696)
Moran, E. et al. 2021. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. The Lancet Infectious Diseases 21(10), pp. 1345-1347. (10.1016/S1473-3099(21)00464-3)
Hurst, J. R. et al. 2021. Granulomatous-lymphocytic interstitial lung disease: an international research prioritisation. ERJ Open Research 7(4), article number: 00467-2021. (10.1183/23120541.00467-2021)
Cooray, S. et al. 2021. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology 60(9), pp. 4373-4378., article number: keaa837. (10.1093/rheumatology/keaa837)
Faustini, S. E. et al. 2021. Development of a high sensitivity ELISA detecting IgG, A & M antibodies to the SARS‐CoV‐2 spike glycoprotein in serum and saliva. Immunology 164(1), pp. 135-147. (10.1111/imm.13349)
Ponsford, M. J., Shillitoe, B. M., Humphreys, I. R., Gennery, A. R. and Jolles, S. 2021. COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency. Current Opinion in Allergy and Clinical Immunology (10.1097/ACI.0000000000000792)
Piza, C. F. S. d. T., Aranda, C. S., Solé, D., Jolles, S. and Condino-Neto, A. 2021. Serum protein electrophoresis may be used as a screening tool for antibody deficiency in children and adolescents. Frontiers in Immunology 12, article number: 712637. (10.3389/fimmu.2021.712637)
Sánchez-Ramón, S., Faure, F., Jolles, S., Leboyer, M. and Tremblay, M. 2021. Editorial: the crossroads between immunological disorders and neuropsychiatric diseases. a case for Schizophrenia. Frontiers in Cellular Neuroscience 15, article number: 733997. (10.3389/fncel.2021.733997)
Harrison, S. C. et al. 2021. Hematopoietic stem cell transplantation resolves the immune deficit associated with STAT3-Dominant-Negative Hyper-IgE Syndrome. Journal of Clinical Immunology 41, pp. 934-943. (10.1007/s10875-021-00971-2)
Jolles, S. et al. 2021. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. European Journal of Haematology 106(4), pp. 439-449. (10.1111/ejh.13580)
Quinti, I., Spadaro, G., Jolles, S. and Condino-Neto, A. 2021. Editorial: The complexity of primary antibody deficiencies. Frontiers in Immunology 12, article number: 635482. (10.3389/fimmu.2021.635482)
Campos, L. C. et al. 2021. Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. Journal of Allergy and Clinical Immunology 147(3), pp. 1104-1107. (10.1016/j.jaci.2020.08.034)
Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58(2) (10.1177/0004563220981106)
Shields, A. M. et al. 2021. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Journal of Allergy and Clinical Immunology 147(3), pp. 870-875., article number: E1. (10.1016/j.jaci.2020.12.620)
Ponsford, M. J. et al. 2021. Increased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study. The Journal of Allergy and Clinical Immunology: In Practice 9(2), pp. 735-744.e6. (10.1016/j.jaip.2020.08.016)
Meyts, I. et al. 2021. Coronavirus Disease 2019 in patients with inborn errors of immunity: an international study. Journal of Allergy and Clinical Immunology 147(2), pp. 520-531. (10.1016/j.jaci.2020.09.010)
Mallick, R., Divino, V., Smith, B. D., Jolles, S., DeKoven, M. and Vinh, D. C. 2021. Infections in secondary immunodeficiency patients treated with Privigen® or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies. Leukemia & Lymphoma 62(14), pp. 3463-3473. (10.1080/10428194.2021.1961233)

2020

Prevot, J. and Jolles, S. 2020. Global immunoglobulin supply: steaming towards the iceberg?. Current Opinion in Allergy and Clinical Immunology 20(6), pp. 557-564. (10.1097/ACI.0000000000000696)
van de Ven, A. A. J. M. et al. 2020. Managing granulomatous–lymphocytic interstitial lung disease in common variable immunodeficiency disorders: e-GLILDnet international clinicians survey. Frontiers in Immunology 11, article number: 606333. (10.3389/fimmu.2020.606333)
Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202(9), pp. 1304-1308. (10.1164/rccm.202007-2778LE)
Mace, E. M. et al. 2020. Human NK cell deficiency as a result of biallelic mutations in MCM10. Journal of Clinical Investigation 130(10), pp. 5272-5286. (10.1172/JCI134966)
Ponsford, M. J. et al. 2020. Hematopoietic stem cell transplantation and vasculopathy associated with STAT3-dominant-negative hyper-IgE syndrome. Frontiers in Pediatrics 8, article number: 575. (10.3389/fped.2020.00575)
Robak, T. et al. 2020. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Advances 4(17), pp. 4136-4146. (10.1182/bloodadvances.2020002003)
Peter, H., Ochs, H. D., Cunningham-Rundles, C., Vinh, D. C., Kiessling, P., Greve, B. and Jolles, S. 2020. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. Journal of Allergy and Clinical Immunology 146(3), pp. 479-491. (10.1016/j.jaci.2020.07.016)
Williams, F., Ponsford, M., El-Shanawany, T., Macdonald, L., Jolles, S. and Williams, P. 2020. Improved anaphylaxis referral rates to specialized services from an emergency department. Clinical and Experimental Allergy 50(8), pp. 973-976. (10.1111/cea.13673)
Ponsford, M. J. et al. 2020. Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). Journal of Clinical Pathology 73, pp. 587-592. (10.1136/jclinpath-2019-206235)
Hadaschik, E. et al. 2020. Europäische Leitlinien (S1) für die Verwendung von hoch dosierten intravenösen Immunglobulinen in der Dermatologie. Hautarzt 71, pp. 542-552. (10.1007/s00105-020-04610-6)
Thaventhiran, J. E. D. et al. 2020. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature 583, pp. 90-95. (10.1038/s41586-020-2265-1)
Brodszki, N. et al. 2020. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management. Journal of Clinical Immunology 40, pp. 576-591. (10.1007/s10875-020-00754-1)
Germenis, A. E. et al. 2020. International consensus on the use of genetics in the management of hereditary angioedema. The Journal of Allergy and Clinical Immunology: In Practice 8(3), pp. 901-911. (10.1016/j.jaip.2019.10.004)

2019

Ponsford, M. J., Pecoraro, A. and Jolles, S. 2019. Clozapine-associated secondary antibody deficiency. Current Opinion in Allergy and Clinical Immunology 19(6), pp. 553-562. (10.1097/ACI.0000000000000592)
Suez, D. et al. 2019. Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. Immunotherapy 11(12), pp. 1057-1065. (10.2217/imt-2019-0057)
Bethune, C. et al. 2019. British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non‐infectious complications of common variable immunodeficiency disorders. Clinical and Experimental Immunology 196(3), pp. 328-335. (10.1111/cei.13272)
Dumas, T., Berry, N. S., Wolfsegger, M., Jolles, S., McCoy, B. and Yel, L. 2019. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. International Immunopharmacology 71, pp. 404-410. (10.1016/j.intimp.2019.03.034)
Gorman, K. M. et al. 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104(5), pp. 948-956. (10.1016/j.ajhg.2019.03.005)
Hong, Y. et al. 2019. Autoinflammation due to homozygous S208 MEFV mutation [Letter]. Annals of the Rheumatic Diseases 78(4), pp. 571-573. (10.1136/annrheumdis-2018-214102)
Ponsford, M. et al. 2019. Clozapine is associated with secondary antibody deficiency. British Journal of Psychiatry 214(2), pp. 83-89. (10.1192/bjp.2018.152)
Patel, S. Y., Carbone, J. and Jolles, S. 2019. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Frontiers in Immunology 10, pp. -., article number: 33. (10.3389/fimmu.2019.00033)
Ponsford, M. J. and Jolles, S. 2019. Antibody deficiency in patients taking clozapine. British Medical Journal 364, article number: 1483. (10.1136/bmj.l483)
Whittam, D. H. et al. 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19(1), pp. 5-10. (10.1136/practneurol-2018-001899)
Tange, C. E. et al. 2019. Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay. Journal of Clinical Laboratory Analysis 33(1), article number: e22627. (10.1002/jcla.22627)
Rolfes, M. et al. 2019. Chronic norovirus infection in primary immune deficiency disorders: an international case series. Diagnostic Microbiology and Infectious Disease 93(1), pp. 69-73. (10.1016/j.diagmicrobio.2018.08.002)

2018

Tallantyre, E. C., Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18(6), pp. 481-488. (10.1097/ACI.0000000000000485)
Mallick, R., Jolles, S., Kanegane, H., Agbor-Tarh, D. and Rojavin, M. 2018. Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a pooled analysis of six Hizentra® studies. Journal of Clinical Immunology 38(8), pp. 886-897. (10.1007/s10875-018-0562-3)
Jolles, S. et al. 2018. Long-term efficacy and safety of Hizentra® in patients with primary immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. Journal of Clinical Immunology 38(8), pp. 864-875. (10.1007/s10875-018-0560-5)
Ponsford, M. J. et al. 2018. Hyper IgE in the allergy clinic-- when is it primary immunodeficiency?. Allergy 73(11), pp. 2122-2136. (10.1111/all.13578)
Hartono, S. P., Vargas-Hernández, A., Ponsford, M. J., Chinn, I. K., Jolles, S., Wilson, K. and Forbes, L. R. 2018. Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency. Journal of Clinical Immunology 38(7), pp. 753-756. (10.1007/s10875-018-0554-3)
Baumann, U., Routes, J. M., Soler-Palacín, P. and Jolles, S. 2018. The lung in primary immunodeficiencies: new concepts in infection and inflammation. Frontiers in Immunology 9, article number: 1837. (10.3389/fimmu.2018.01837)
Parker, A. R., Bradley, C., Harding, S., Sánchez-Ramón, S., Jolles, S. and Kiani-Alikhan, S. 2018. Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity. Journal of Immunological Methods 459, pp. 1-10. (10.1016/j.jim.2018.05.013)
Whitworth, J. et al. 2018. Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes. American Journal of Human Genetics 103(1), pp. 3-18. (10.1016/j.ajhg.2018.04.013)
Evans, C. et al. 2018. Measurement of Typhim Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency. Clinical and Experimental Immunology 192(3), pp. 292-301. (10.1111/cei.13105)
Shillitoe, B. et al. 2018. The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017. Clinical and Experimental Immunology 192(3), pp. 284-291. (10.1111/cei.13125)
Tange, C. E. et al. 2018. Quantification of human complement C2 protein using an automated turbidimetric immunoassay. Clinical Chemistry and Laboratory Medicine 56(9), pp. 1498-1506. (10.1515/cclm-2017-1068)
Maccari, M. E. et al. 2018. Disease evolution and response to rapamycin in activated phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Frontiers in Immunology 9, article number: 543. (10.3389/fimmu.2018.00543)
Tallantyre, E., Whittam, D. H., Jolles, S., Paling, D., Constantinescu, C., Robertson, N. and Jacob, A. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265(5), pp. 1115-1122. (10.1007/s00415-018-8812-0)
Stubbs, A. et al. 2018. Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. Clinical and Experimental Immunology 191(2), pp. 212-219. (10.1111/cei.13068)
Pecoraro, A. et al. 2018. Validation of calculated globulin (CG) as a screening test for antibody deficiency in an Italian University Hospital. Current Pharmaceutical Biotechnology 19(9), pp. 728-733. (10.2174/1389201019666180808163311)

2017

Hashem, H. et al. 2017. Hematopoietic stem cell transplantation rescues the hematological, immunological and vascular phenotype in DADA2. Blood 130(24), pp. 2682-2688., article number: 798660. (10.1182/blood-2017-07-798660)
Krivan, G., Jolles, S., Lopes Granados, E., Paolantonacci, P., Ouaja, R., Alfa Cissé, O. and Bernatowska, E. 2017. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. American Journal of Clinical and Experimental Immunology 6(5), pp. 76-83.
Kiessling, P. et al. 2017. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Science Translational Medicine 9(414) (10.1126/scitranslmed.aan1208)
Jolles, S. et al. 2017. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clinical and Experimental Immunology 190(2), pp. 226-234. (10.1111/cei.13012)
Miot, C. et al. 2017. Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphicIKBKG/NEMO mutations. Blood 130(12), pp. 1456-1467. (10.1182/blood-2017-03-771600)
Hurst, J. R. et al. 2017. British Lung Foundation/United Kingdom Primary Immunodeficiency Network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. The Journal of Allergy and Clinical Immunology: In Practice 5(4), pp. 938-945. (10.1016/j.jaip.2017.01.021)
Griffiths, R., El-Shanawany, T., Jolles, S., Selwood, C., Heaps, A., Carne, E. and Williams, P. 2017. Comparison of the performance of Skin Prick, ImmunoCAP, and ISAC tests in the diagnosis of patients with allergy. International Archives of Allergy and Immunology 172(4), pp. 215-223. (10.1159/000464326)
Jolles, S., Chapel, H. and Litzman, J. 2017. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clinical and Experimental Immunology 188(3), pp. 333-341. (10.1111/cei.12915)
Wasserman, R. L., Melamed, I. R., Stein, M. R., Jolles, S., Norton, M. and Moy, J. N. 2017. Evaluation of the safety, tolerability, and pharmacokinetics of gammaplex® 10% versus gammaplex® 5% in subjects with primary immunodeficiency. Journal of Clinical Immunology 37(3), pp. 301-310. (10.1007/s10875-017-0383-9)
Enk, A. et al. 2017. Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie. JDDG 15(2), pp. 227-238. (10.1111/ddg.13013_g)
Enk, A. et al. 2017. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. JDDG 15(2), pp. 228-241. (10.1111/ddg.13013)
Carne, E., Ponsford, M., El-Shanawany, T. and Jolles, S. 2017. Skin necrosis following subcutaneous immunoglobulin (SCIg). Journal of Clinical Immunology 37(1), pp. 27-28. (10.1007/s10875-016-0346-6)
Stray-Pedersen, A. et al. 2017. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. Journal of Allergy and Clinical Immunology 139(1), pp. 232-245. (10.1016/j.jaci.2016.05.042)
Jolles, S., Carne, E., Brouns, M., El-Shanawany, T., Williams, P., Marshall, C. and Fielding, P. 2017. FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clinical & Experimental Immunology 187(1), pp. 138-145. (10.1111/cei.12856)
Borte, M. et al. 2017. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. Clinical and Experimental Immunology 187(1), pp. 146-159. (10.1111/cei.12866)

2016

Nanthapisal, S. et al. 2016. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis & Rheumatology 68(9), pp. 2314. (10.1002/art.39699)
aan de Kerk, D. J. et al. 2016. Phenotypic and Functional Comparison of Class Switch Recombination Deficiencies with a Subgroup of Common Variable Immunodeficiencies. Journal of Clinical Immunology 36(7), pp. 656-666. (10.1007/s10875-016-0321-2)
Williams, P., Önell, A., Baldracchini, F., Hui, V., Jolles, S. and El-Shanawany, T. 2016. Evaluation of a novel automated allergy microarray platform compared with three other allergy test methods. Clinical and Experimental Immunology 184(1), pp. 1-10. (10.1111/cei.12721)

2015

Carne, E., Ponsford, M., El-Shanawany, T., Williams, P., Pickersgill, T. and Jolles, S. 2015. Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency. Journal of Clinical Pathology 69(1), pp. 87-88. (10.1136/jclinpath-2015-202901)
Brent, J. et al. 2015. Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia. Clinical and Experimental Immunology 184(1), pp. 73-82. (10.1111/cei.12748)
Holding, S. and Jolles, S. 2015. Current screening approaches for antibody deficiency. Current Opinion in Allergy and Clinical Immunology 15(6), pp. 547-555. (10.1097/ACI.0000000000000222)
Ponsford, M. et al. 2015. Facilitated subcutaneous immunoglobulin (fSCIg) therapy - practical considerations. Clinical and Experimental Immunology 182(3), pp. 302-313. (10.1111/cei.12694)
Longhurst, H. J. et al. 2015. C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clinical and Experimental Immunology 180(3), pp. 475-483. (10.1111/cei.12584)
Holding, S., Khan, S., Sewell, W. A., Jolles, S. and Dore, P. C. 2015. Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project. Annals of Clinical Biochemistry 52(3), pp. 319-326. (10.1177/0004563214545791)
Jolles, S., Orange, J. S., Gardulf, A., Stein, M. R., Shapiro, R., Borte, M. and Berger, M. 2015. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clinical and Experimental Immunology 179(2), pp. 146-160. (10.1111/cei.12485)

2014

Jolles, S. 2014. Subclinical infection and dosing in primary immunodeficiencies. Clinical and Experimental Immunology 178(S1), pp. 67-69. (10.1111/cei.12516)
Jolles, S., Jordan, S. C., Orange, J. S. and van Schaik, I. N. 2014. Immunoglobulins: current understanding and future directions. Clinical and Experimental Immunology 178, pp. 163-168. (10.1111/cei.12555)
Chakraborty, P. K. et al. 2014. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 124(18), pp. 2867-2871. (10.1182/blood-2014-08-591370)
Heaps, A. et al. 2014. The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis. Clinical and Experimental Immunology 177(2), pp. 483-490. (10.1111/cei.12334)
Dickinson, R. E. et al. 2014. The evolution of cellular deficiency in GATA2 mutation. Blood 123(6), pp. 863-874. (10.1182/blood-2013-07-517151)
Jolles, S., Borte, M., Nelson, R. P., Rojavin, M., Bexon, M., Lawo, J. and Wasserman, R. L. 2014. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. Clinical Immunology 150(2), pp. 161-169. (10.1016/j.clim.2013.10.008)
Edgar, J. D. M. et al. 2014. The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012. Clinical and Experimental Immunology 175(1), pp. 68-78. (10.1111/cei.12172)
Jolles, S. et al. 2014. A UK national audit of hereditary and acquired angioedema. Clinical and Experimental Immunology 175(1), pp. 59-67. (10.1111/cei.12159)

2013

Jolles, S. 2013. The variable in common variable immunodeficiency: A disease of complex phenotypes. The Journal of Allergy and Clinical Immunology: In Practice 1(6), pp. 545-556. (10.1016/j.jaip.2013.09.015)
Jolles, S. 2013. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. ImmunoTargets and Therapy 2, pp. 125-133. (10.2147/ITT.S31136)
Wiseman, D. H. et al. 2013. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 122(1), pp. 112-123. (10.1182/blood-2012-08-439083)
Berger, M., Jolles, S., Orange, J. S. and Sleasman, J. W. 2013. Bioavailability of IgG Administered by the subcutaneous route. Journal of Clinical Immunology 33(5), pp. 984-990. (10.1007/s10875-013-9876-3)
Cossburn, M. D. et al. 2013. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 80(1), pp. 55-61. (10.1212/WNL.0b013e31827b5927)

2012

Orange, J. S. et al. 2012. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clinical and Experimental Immunology 169(2), pp. 172-181. (10.1111/j.1365-2249.2012.04594.x)
Beeton, M. L., Daha, M. R., El-Shanawany, T., Jolles, S., Kotecha, S. and Spiller, O. B. 2012. Serum killing of 'ureaplasma parvum' shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients. Immunobiology 217(2), pp. 187-194. (10.1016/j.imbio.2011.07.009)

2011

Borte, M. et al. 2011. Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. Journal of Clinical Immunology 31(5), pp. 752-761. (10.1007/s10875-011-9557-z)
Jolles, S. and Sleasman, J. W. 2011. Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach. Advances in Therapy 28(7), pp. 521-533. (10.1007/s12325-011-0036-y)
Jolles, S. et al. 2011. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clinical Immunology 141(1), pp. 90-102. (10.1016/j.clim.2011.06.002)
Suan, D., Koutts, J., Tschuchnigg, M., Shingde, M., Jolles, S. and Fulcher, D. A. 2011. Cytotoxic T-cell lymphoma complicating common variable immunodeficiency. Pathology 43(1), pp. 75-78. (10.1097/PAT.0b013e3283419ec1)

2010

El-Shanawany, T., Seddon, L. C., Jolles, S., Carne, E., Dowd, H. D. and Williams, P. E. 2010. Patients with anaphylaxis in accident and emergency are not referred to specialised allergy services [Letter]. Journal of Clinical Pathology 63(4), pp. 375. (10.1136/jcp.2009.068577)
Ng, W. et al. 2010. Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Journal of Allergy and Clinical Immunology 126(5), pp. 1006-1015. (10.1016/j.jaci.2010.08.027)
Knight, E., Carne, E., Novak, B., El-Shanawany, T., Williams, P. E., Pickersgill, T. and Jolles, S. 2010. Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency [Letter]. Journal of Clinical Pathology 63(9), pp. 846-847. (10.1136/jcp.2010.076828)

2009

Masilamani, K., Jolles, S., Huddart, S. and Tuthill, D. 2009. Successful dietary treatment of recurrent intussusception [Letter]. Archives of Disease in Childhood 94(3), pp. 248-249. (10.1136/adc.2008.146290)
Jolles, S., Kaveri, S. V. and Orange, J. 2009. Foreword. Clinical and Experimental Immunology 158(S1), pp. 1. (10.1111/j.1365-2249.2009.04021.x)
Hartung, H., Mouthon, L., Ahmed, R., Jordan, S., Laupland, K. B. and Jolles, S. 2009. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clinical and Experimental Immunology 158(S1), pp. 23-33. (10.1111/j.1365-2249.2009.04024.x)
Jolles, S., Kaveri, S. V. and Orange, J. 2009. Current understanding and future directions. Clinical and Experimental Immunology 158(S1), pp. 68-70. (10.1111/j.1365-2249.2009.04029.x)
El-Shanawany, T., Jolles, S., Unsworth, D. J. and Williams, P. A. 2009. A recipient of immunoglobulin from a donor who developed vCJD [Letter]. Vox Sanguinis 96(3), pp. 270. (10.1111/j.1423-0410.2008.01148.x)
van Raam, B. J., van Bruggen, R., Tool, A. T. J., Jansen, M. H., Warris, A., Jolles, S. and Kuijpers, T. W. 2009. Nuclear factor- B is not essential for NADPH oxidase activity in neutrophils from anhidrotic ectodermal dysplasia patients [Letter]. Blood 113(21), pp. 5362-5363. (10.1182/blood-2009-02-203562)

2008

El-Shanawany, T., Williams, P. E. and Jolles, S. 2008. Clinical immunology review series: an approach to the patient with anaphylaxis. Clinical and experimental immunology 153(1), pp. 1-9. (10.1111/j.1365-2249.2008.03694.x)
Roy, E., Brennan, J., Jolles, S. and Lowrie, D. B. 2008. Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. Tuberculosis 88(3), pp. 197-202. (10.1016/j.tube.2007.11.005)
Williams, P. E., Sewell, W. A. C., Bunn, C., Pumphrey, R., Read, G. and Jolles, S. 2008. Clinical Immunology Review Series: An approach to the use of the immunology laboratory in the diagnosis of clinical allergy. Clinical and Experimental Immunology 153(1), pp. 10-18. (10.1111/j.1365-2249.2008.03695.x)

2007

El-Shanawany, T. and Jolles, S. 2007. Intravenous Immunoglobulin and Autoimmune Disease. Annals of the New York Academy of Sciences 1110(1), pp. 507-515. (10.1196/annals.1423.054)
El-Shanawany, T., Williams, P. E. and Jolles, S. 2007. Response of refractory ITP in a patient with common variable immunodeficiency (CVID) to treatment with rituximab. Journal of Clinical Pathology 60(6), pp. 715-716. (10.1136/jcp.2006.041426)

2005

Roy, E. et al. 2005. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infection and Immunity 73(9), pp. 6101-9. (10.1128/IAI.73.9.6101-6109.2005)

Past projects